Company

Our Mission:

Prominex is focused on the development and manufacture of molecular diagnostic assays for Point-of-Care (POC) infectious disease testing. Our Validex System is a transformative molecular diagnostic testing solution for near patient care settings. The proprietary molecular chemistry and detection technologies incorporated into our Validex System enables the development of ultrafast, central laboratory quality, highly multiplexed, and low-cost MDx assays.

Prominex Key Facts

Company was founded in 2016 and is headquartered at the JLABS facility in San Diego, CA.
Initial assay development focus is on Sexually Transmitted Infections and Respiratory Tract Infections.
Broad IP portfolio protects our novel enzyme, molecular chemistry and detection technologies.
Leadership team has proven experience in molecular diagnostics and medical devices.
Seed capital financing provided by Casdin Capital LLC and the founding CEO.

Leadership Team

Paul Thomas

Chief Executive Officer and Founder

Contact

Prior to Prominex, Mr. Thomas served as the chief executive officer of Roka Bioscience, Inc., a molecular diagnostic company focused on food safety, from 2009 until 2017. Mr. Thomas previously served as chairman, chief executive officer and president of LifeCell Corporation, a publicly traded regenerative medicine company from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. Prior to joining LifeCell, he held various senior positions during a 15-year tenure with the Pharmaceutical Products Division of Ohmeda Inc., a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas currently serves on the board of directors of AbioMed (NASDAQ: ABMD) and RTI Surgical (NASDAQ: RTIX). He received his bachelor of science in chemistry from St. Michael’s College, completed his postgraduate studies in chemistry at the University of Georgia and received his master of business administration from Columbia University.

Paul Gargan PhD

Chief Commercial Officer and Co-founder

Contact

Prior to Prominex, Dr. Gargan operated his own advisory business, The Causeway Advisory Group, providing strategic direction, M&A services, transaction negotiation, fund raising, technology evaluation, due diligence and target identification for diagnostic, medical device and biotech companies. Dr. Gargan previously held a variety of senior leadership positions in business development and strategic planning for 15 years at Gen-Probe (now Hologic) where he spearheaded the formation, acquisition, integration and management of numerous new businesses, strategic alliances and corporate collaborations. During his tenure at Gen-Probe, he negotiated over 120 transactions generating more than $100 million in license fees and royalty income and led to over $2 billion in product sales. Dr. Gargan also led Gen-Probe’s M&A team for 3 years acquiring several key companies and technologies representing cumulative investments of over $250 million. He received his bachelor of science in Chemistry and PhD in Biochemistry from Queen’s University and master of business administration from the University of Notre Dame.

Mick Becker PhD

Chief Technology Officer and Co-founder

Contact

Dr. Becker is the inventor of Prominex’s novel CHASE (Coupled Hairpin Amplification System) technology. Prior to Prominex, Dr. Becker served as the Vice President of R&D and Chief Scientific Officer of Roka Bioscience, Inc., a molecular diagnostic company focused on food safety, from 2009 until 2017. Dr. Becker previously served in a variety of senior leadership positions in research for 16 years at Gen-Probe (now Hologic) where he invented many of their key core technologies that are today covered by more than 85 issued patents. Prior to joining Gen-Probe, Dr. Becker was an Associate Professor in the Institute of Biosciences and Technology at Texas A&M University, an Assistant Professor in the Department of Biological Sciences at the University of Pittsburgh and an Anna Fuller Postdoctoral Fellow at Harvard University with James C. Wang. He received his PhD in Chemistry from Caltech under Peter B. Dervan and has published over 175 papers and patents in the field of nucleic acids.

Anja Bubeck-Barrett PhD

Director Research

Contact

Dr. Bubeck-Barrett is leading the technical team developing the novel CHASE technology. Dr. Bubeck-Barrett has over a decade of leadership experience in molecular diagnostic assay research and development. Prior to joining Prominex, Dr. Bubeck-Barrett held various leadership positions in Research and Assay Development at Roka Bioscience, a molecular diagnostic company focused on food safety from 2010 to 2017. Dr. Bubeck-Barrett joined Gen-Probe Inc. (now Hologic) in 2005 and during her 5 year tenure contributed to essential research of core technologies. Dr. Bubeck-Barrett received her PhD in Genetics and Virology from the University of Tübingen, Germany and was a Research Fellow at the University of Munich. She received a DFG fellowship for Postdoctoral Studies at the Scripps Research Institute in La Jolla from 2004 to 2005.

Board of Directors

Paul Thomas

Prior to Prominex, Mr. Thomas served as the chief executive officer of Roka Bioscience, Inc., a molecular diagnostic company focused on food safety, from 2009 until 2017. Mr. Thomas previously served as chairman, chief executive officer and president of LifeCell Corporation, a publicly traded regenerative medicine company from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. Prior to joining LifeCell, he held various senior positions during a 15-year tenure with the Pharmaceutical Products Division of Ohmeda Inc., a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas currently serves on the board of directors of AbioMed (NASDAQ: ABMD) and RTI Surgical (NASDAQ: RTIX). He received his bachelor of science in chemistry from St. Michael’s College, completed his postgraduate studies in chemistry at the University of Georgia and received his master of business administration from Columbia University.

Nick Valeriani

Mr. Valeriani recently retired as the chief executive officer of West Health, The Gary and Mary West Health Institute, an independent nonprofit medical research organization that works to create new and more effective ways of delivering healthcare at lower costs, a position he held since 2012. Previously, Mr. Valeriani served 34 years in key positions at Johnson & Johnson, including company group chairman of Johnson & Johnson Ortho-Clinical Diagnostics; vice president, office of strategy and growth; and as worldwide chairman, medical devices and diagnostics, and corporate vice president, human resources. Mr. Valeriani also served on the executive committee of Johnson & Johnson during his tenure. He currently serves on the board of directors of Edwards Lifesciences (NYSE: EW), and RTI Surgical (NASDAQ: RTIX), as well as the Robert Wood Johnson University Hospital. Mr. Valeriani received a bachelor’s degree in industrial engineering and a master of business administration from Rutgers University.

Eli Casdin

Mr. Casdin is the Chief Investment Officer of Casdin Capital, a New York-based investment firm focused on funding innovation for life science, biotechnology and pharmaceutical companies. Mr. Casdin has spent the past 13 years analyzing and investing in disruptive technologies and business models in Life Sciences and Healthcare. He holds a B.S. from Columbia University and MBA from Columbia Business School.

Shaun Rodriguez, PhD

Dr. Rodriguez is a Senior Research Analyst for Casdin Capital, a New York-based investment firm focused on funding innovation for life science, biotechnology and pharmaceutical companies. Dr. Rodriguez has spent the past 9 years analyzing and investing in Life Sciences & Healthcare companies. He holds a B.S. from University of Maine, M.S. from Tufts University, PhD from Harvard University.

Grow your career with us

Come join the team that’s changing the molecular diagnostics landscape and revolutionizing patient care! Prominex is an equal opportunity employer and is committed to a dynamic, diverse and inclusive workplace for all.